Sentences with phrase «myeloma cells in»

The researchers then tested the capacity of the modified cells to kill human multiple myeloma cells in laboratory studies and an animal model.

Not exact matches

Multiple myeloma causes tumors to grow in the bone marrow, preventing the production of normal blood cells.

Analyzing a database of nearly 800 multiple myeloma patient samples, they discovered that 162 patients with low ADAR1 levels in their tumor cells survived significantly longer over a three - year period compared to 159 patients with high ADAR1 levels.

«Several major advances in recent years have been good news for multiple myeloma patients, but those new drugs only target terminally differentiated cancer cells and thus can only reduce the bulk of the tumor,» said Jamieson, who is also deputy director of the Sanford Stem Cell Clinical Center, director of the CIRM Alpha Stem Cell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego HeaCell Clinical Center, director of the CIRM Alpha Stem Cell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego HeaCell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego Heacell research at Moores Cancer Center at UC San Diego Health.

They also determined that blocking the enzyme reduces multiple myeloma regeneration in experimental models derived from patient cancer cells.

They are also testing inhibitors of JAK2, a molecule that influences ADAR1 activity, for their ability to eliminate cancer stem cells in multiple myeloma models.

Researchers used tissue and blood samples to show that the gammopathy (a precursor to myeloma) in both mice and patients with Gaucher disease is triggered by specific lipids, and that the antibodies made by tumor cells in nearly a third of myeloma patients are directed against such lipids.

An update search enlarged the pool of study data, but did not change the content of the conclusion of the benefit assessment of stem cell transplantation (SCT) for multiple myeloma conducted in 2012.

In our study, as BMI increased, we started seeing an increase in the ability of multiple myeloma cells to adhere, which causes the cancer to better anchor,» DeCicco - Skinner explaineIn our study, as BMI increased, we started seeing an increase in the ability of multiple myeloma cells to adhere, which causes the cancer to better anchor,» DeCicco - Skinner explainein the ability of multiple myeloma cells to adhere, which causes the cancer to better anchor,» DeCicco - Skinner explained.

But in multiple myeloma, plasma cells grow out of control in the bone marrow, crowding out healthy cells.

In mice, the Runx2 knock - in myeloma cells produced greater tumor growth and a wider spread of disease compared with the original myeloma cells; conversely, the Runx2 knock - down cells had less tumor growth and disease spreaIn mice, the Runx2 knock - in myeloma cells produced greater tumor growth and a wider spread of disease compared with the original myeloma cells; conversely, the Runx2 knock - down cells had less tumor growth and disease spreain myeloma cells produced greater tumor growth and a wider spread of disease compared with the original myeloma cells; conversely, the Runx2 knock - down cells had less tumor growth and disease spread.

«Taken together, these results support the hypothesis that multiple myeloma cells express bone - related genes in a Runx2 - dependent fashion that mimics bone marrow resident cells and likely contributes to tumor survival and growth in the bone microenvironment,» Yang and colleagues wrote in the paper.

«Therefore, the targeting of Runx2 expression in multiple myeloma cells may represent a new therapeutic strategy for the treatment of aggressive multiple myeloma.»

«This suggests that Runx2 levels in myeloma cells may be a gene predictor of a patient's prognosis, good or bad,» Yang said.

Researchers have designed a nanoparticle - based therapy that is effective in treating mice with multiple myeloma, a cancer of immune cells in the bone marrow.

«We know multiple myeloma cells will anchor into bone marrow, and fat cells in the bone marrow will support the growth and spread of the cancer.

Healthy plasma cells produce antibodies that fight infection in the body, but myeloma cells produce high levels of abnormal antibodies that, when the cancer cells accumulate, they crowd out production of other important blood cells, both red and white.

In humans, a comparison of bone marrow from 14 normal bone marrow donors, 35 multiple myeloma patients and 11 patients with a noncancerous condition called monoclonal gammopathy of undetermined significance (MGUS) showed that Runx2 levels were significantly higher in the multiple myeloma cellIn humans, a comparison of bone marrow from 14 normal bone marrow donors, 35 multiple myeloma patients and 11 patients with a noncancerous condition called monoclonal gammopathy of undetermined significance (MGUS) showed that Runx2 levels were significantly higher in the multiple myeloma cellin the multiple myeloma cells.

Researchers at Washington University School of Medicine in St. Louis have developed a nanotherapy that is effective in treating mice with multiple myeloma, a cancer of bone marrow immune cells.

The researchers also tested a Runx2 knock - down variant of a human multiple myeloma cell line and found that it produced significantly less tumor growth in immunodeficient mice than the original human multiple myeloma cells.

Whether investigating fat cells, immunotherapy or use of the CRISPR - Cas 9 gene - editing tool, which a federal panel recently approved for a select number of patients suffering from three types of cancers, including multiple myeloma, approaches beyond attacking cancer cells are needed in the fight against many cancers.

The study, «Lenalidomide (LEN) maintenance (MNTC) after high - dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta - analysis (MA) of overall survival (OS),» is ASCO 2016 abstract no. 8001 and will be discussed during the Hematologic Malignancies — Plasma Cell Dyscrasia oral abstract session Friday, Juncell transplant (ASCT) in multiple myeloma (MM): A meta - analysis (MA) of overall survival (OS),» is ASCO 2016 abstract no. 8001 and will be discussed during the Hematologic Malignancies — Plasma Cell Dyscrasia oral abstract session Friday, JunCell Dyscrasia oral abstract session Friday, June 3.

Being overweight or obese has been known to increase the risk of multiple myeloma, a cancer of the plasma cells in the blood and bone marrow that develops more often after age 60.

In multiple myeloma, normal plasma cells transform into malignant myeloma cells and produce large quantities of toxic abnormal immunoglobulin called monoclonal protein that can damage multiple organs.

Multiple myeloma is preceded by a blood disorder called monoclonal gammopathy of undetermined significance (MGUS) in which abnormal plasma cells produce many copies of an antibody protein.

The group looked at an oncogene, AF1q discovered in Tse's lab, which is expressed in hematological cancer cells and is known to be related to multiple myeloma.

Multiple myeloma is a cancer of plasma cells in the blood that causes tumor growths in bone marrow.

Using an approach developed at Maisonneuve - Rosemont, consisting of an autograft to reduce tumour mass followed by a family allograft three to four months later to clean the bone marrow of myeloma cells with immune cells from a family donor (immunotherapy), the study resulted in a total cure rate of 41 %, a record level using this strategy.

Bortezomib, used most commonly in treating multiple myeloma, is a proteasome inhibitor that prevents cancer cells from clearing toxic material.

«The treatment of multiple myeloma has improved significantly in recent years with the introduction of therapies such as proteasome inhibitors [which interfere with tumor cells» protein - disposal system] and potent immuno - modulatory agents,» said the paper's senior author and lead investigator, Paul Richardson, MD, clinical program leader and director of clinical research at Dana - Farber's Jerome Lipper Multiple Myeloma Center, and the R.J. Corman professor at Harvard Medical myeloma has improved significantly in recent years with the introduction of therapies such as proteasome inhibitors [which interfere with tumor cells» protein - disposal system] and potent immuno - modulatory agents,» said the paper's senior author and lead investigator, Paul Richardson, MD, clinical program leader and director of clinical research at Dana - Farber's Jerome Lipper Multiple Myeloma Center, and the R.J. Corman professor at Harvard Medical Myeloma Center, and the R.J. Corman professor at Harvard Medical School.

Relative to reactions on naked DNA, there are changes (protections and enhancements) in the reactivity of guanine residues to dimethyl sulfate within the enhancer sequence in myeloma, B, and early B cells, whereas virtually no alterations appear in cells of non-B lineage.

«T - cell receptor therapy achieves encouraging clinical responses in multiple myeloma: NY - ESO T cell receptor therapy found to be safe, with no cytokine release syndrome cases.»

After being infused back into patients» bodies, these newly built cells both multiply and seek out a peptide expressed by the antigens NY - ESO - 1 and LAGE - 1 found in multiple myeloma cancer cells.

Results from a clinical trial investigating a new T cell receptor (TCR) therapy that uses a person's own immune system to recognize and destroy cancer cells demonstrated a clinical response in 80 percent of multiple myeloma patients with advanced disease after undergoing autologous stem cell transplants (ASCT).

Multiple myeloma is a cancer of the infection - fighting plasma cells, part of the immune system found mainly in bone marrow.

In examining these remaining myeloma cells, the Yale team discovered a previously unidentified biologic pathway induced by the immune modulating drugs that enabled the residual cancer cells to survive and proliferate.

Antibodies only bind to target cells Peptide antibodies developed by Kwak and co-discoverer, Hong Qin, Ph.D., assistant professor of Lymphoma / Myeloma, wipe out MDSCs in the blood, spleen and tumor cells of mice without binding to other white blood cells or dendritic cells involved in immune response.

In the 1990s the U.S. Food and Drug Administration approved its use in the treatment of both multiple myeloma (a form of cancer that affects plasma cells) and the complications of leprosIn the 1990s the U.S. Food and Drug Administration approved its use in the treatment of both multiple myeloma (a form of cancer that affects plasma cells) and the complications of leprosin the treatment of both multiple myeloma (a form of cancer that affects plasma cells) and the complications of leprosy.

The discovery was made by developing a mouse model of the disease that enabled researchers to track which of 15 genetic groups — or subclones — of myeloma cells spread beyond their initial site in the animals» hind legs.

The team designed a different approach to study the therapy in myeloma, adding in an infusion of the patient's own stem cells along with their lymphodepleting chemotherapy (melphalan), followed by CTL019 infusion about two weeks later.

Although it is among the most highly metastatic of all cancers, multiple myeloma is driven to spread by only a subset of the myeloma cells within a patient's body, researchers at Dana - Farber Cancer Institute have found in a study presented at the annual meeting of the American Society of Hematology (ASH).

A new study by researchers at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) provides evidence that genetically modifying immune cells might effectively treat multiple myeloma, a disease that remains incurable and will account for an estimated 24,000 new cases and 11,100 deaths in 2014

Multiple myeloma is a blood cancer that forms in a type of white blood cell called a plasma cell.

The researchers grew the modified cells in the lab to increase their numbers and then injected them into an animal model where they again killed human myeloma cells.

Bradner and Mitsiades had reported in Cell in 2011 that the inhibitor blocks the Myc cancer gene and thereby slows the growth of multiple myeloma tumors in mice.

Poseida Announces Initial Phase 1 Data for P - BCMA - 101 CAR - T Stem Cell Memory Product in Patients with Relapsed / Refractory Multiple Myeloma

on Poseida Announces Initial Phase 1 Data for P - BCMA - 101 CAR - T Stem Cell Memory Product in Patients with Relapsed / Refractory Multiple Myeloma

We have one of the most comprehensive CAR T cell programs in the world, with 14 CAR T clinical trials ongoing and plans to open numerous additional trials in the coming year, including for patients with multiple myeloma, prostate cancer, liver cancer and breast cancer.

The laboratory is interested in mechanisms by which interactions between neutrophils and multiple myeloma cells promote disease progression and chemoresistance.

Multiple myeloma preferentially localizes in the bone marrow where the majority of surrounding cells are represented by mature and immature neutrophils.